
Centauri Therapeutics selects first clinical candidate, for immunotherapeutic treatment of Gram-negative bacterial infections
Centauri Therapeutics Limited (Centauri), an immunotherapy company with a unique and proprietary platform technology applicable across a wide range of therapeutic indications, today announced the selection of its first clinical candidate in the ABX-01 programme. Based on the Company’s Alphamer® platform, the compound is designed to target serious Gram-negative bacterial…

Centauri Therapeutics awarded £1M grant under new PACE programme to advance immunotherapy platform in anti-infectives
Centauri is excited to announce that we have been selected to receive a £1M grant under the first round of @PACE-AMR funding which will support…